Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

990 results about "Binding protein" patented technology

A binding protein is any protein that acts as an agent to bind two or more molecules together. Examples include: DNA-binding protein Single-strand binding protein Telomere-binding protein RNA-binding protein Poly-binding protein Nuclear cap-binding protein complex CREB-binding protein Calcium-binding protein Calcium-binding protein 1 S100 calcium-binding protein A1 TATA-binding protein Actin-binding protein Penicillin binding proteins Retinol binding protein Retinol binding protein 4 EP300 Binding immunoglobulin protein Odorant binding protein Lipopolysaccharide-binding protein C4b-binding protein Rap GTP-binding protein Calmodulin-binding proteins Iron-binding proteins Thyroxine-binding proteins Folate-binding protein Sterol regulatory element-binding protein GTP-binding protein Retinaldehyde-binding protein 1 Ccaat-enhancer-binding proteins Androgen-binding protein Maltose-binding protein Phosphatidylethanolamine binding protein 1 Syntaxin binding protein 3 Insulin-like growth factor-binding protein Methyl-CpG-binding domain protein 2 Growth hormone-binding protein Vitamin D-binding protein Syntaxin binding protein 2 Oxysterol-binding protein E3 binding protein

Knockdown or knockout of one or more of TAP2, NLRC5, B2m, TRAC, RFX5, RFXAP and RFXANK to mitigate t cell recognition of allogeneic cell products

Provided herein are engineered immune cells and populations thereof for administration to patients to treat cancer (e.g., solid tumors or liquid tumors) and other conditions. The cells are engineered to functionally express a reduced level of one or more of RFX5, NLRC5, TAP2, β2m, TRAC, RFXAP, CIITA and RFXANK. The cells optionally are further engineered to express one or more than one additional protein such as an antigen binding protein (e.g., a chimeric antigen receptor (CAR) or T cell receptor) to target tumor cells or other damaged cells in the patient and / or to express other genes at a reduced level. Also provided are methods of making and using the engineered cells, compositions and kits comprising them, and methods of treating by administering the cells and the compositions.
Owner:ALLOGENE THERAPEUTICS INC

Kit for detecting multiple extracellular vesicles miRNAs based on TtAgo-driven rolling circle amplification technology and application thereof

The invention discloses a kit for detecting miRNAs of multiple extracellular vesicles based on a TtAgo-driven rolling circle amplification technology and application of the kit, a platform combines TtAgo protein and RCA reaction, cooperates with endonuclease activity and DNA polymerase activity of TtAgo, accurately controls reaction kinetic balance between temperature and enzyme activity, not only does not damage the cutting activity of TtAgo, but also can detect miRNAs of multiple extracellular vesicles. The method provided by the invention can be used for detecting multiple extracellular vesicles miRNAs, ensures strong polymerization amplification performance, creates a strong one-step single-tube experiment, greatly simplifies the experimental process, shortens the detection time, realizes ultra-sensitive and specific detection of nucleic acid markers, and can be used for detecting multiple extracellular vesicles miRNAs.
Owner:THE FIRST AFFILIATED HOSPITAL OF ARMY MEDICAL UNIV

Engineered escherichia coli for producing 5-ALA (5-aminoacetophenone) by anaerobic fermentation method as well as preparation method and fermentation method thereof

The invention discloses an escherichia coli engineering bacterium for producing 5-ALA by an anaerobic fermentation method as well as a construction method and a fermentation method of the escherichia coli engineering bacterium. The engineering bacterium is constructed by taking escherichia coli (E. coli) ZX11 as a host and performing heterologous expression on 5-ALA synthetase (HemA) from rhodobacter capsulatus. In order to improve the soluble expression level of the HemA, the HemA is subjected to fusion expression with a maltose binding protein (MBP) tag. Furthermore, the engineering bacterium can also heterologously express a visual purple protein (PR) fused with the MBP tag. The construction method of the engineering bacteria comprises the following steps: sequentially cloning the MBP-HemA fusion gene and the PR gene to an expression vector and transferring into host bacteria. By utilizing the engineering bacteria provided by the invention, anaerobic fermentation can be carried out in a culture medium taking glucose as a carbon source, and 5-ALA can be efficiently synthesized. The invention provides an effective way for realizing green and energy-saving anaerobic biological manufacturing of 5-ALA.
Owner:SOUTHWEST UNIV

Application of LcCBP60b-LcALY2 molecular module in regulation and control of growth and development and maturing rate of leymus chinensis

The invention belongs to the technical field of plant genetic engineering, and discloses application of an LcCBP60b-LcALY2 molecular module in regulation and control of growth and development and maturing rate of leymus chinensis. The invention discovers that the calmodulin binding protein coding gene LcCBP60b negatively regulates the growth and development and the maturing rate of the leymus chinensis for the first time, and a yeast double-impurity experiment discovers that the LcCBP60b interacts with the LcALY2 protein to regulate the related characters of the maturing rate of the leymus chinensis. The LcCBP60b negatively regulates the activity of the LcALY2 protein and inhibits the regulation effect of the LcALY2 coded THO protein complex 4B in the flowering and ear forming process of leymus chinensis. The LcCBP60b-LcALY2 molecular module verified by the invention provides a new perspective for deeply understanding a Leymus chinensis fruiting regulation mechanism, and provides a direct molecular target for directionally creating new varieties of high-fruiting-rate pasture and cereal crops.
Owner:CHINA AGRI UNIV

Ph-sensitive antibodies

A major challenge in the field of antibody-based therapeutics is the development of antibodies that have longer duration of action, longer half-life and can be delivered to a patient at lower doses. The current methods to achieve this aim depend on the engineering modification of the pH-dependent antigen binding properties of the antibodies, which is very strenuous and generally requires further optimization of the pH-sensitive interactions in a low-throughput, individualized manner because these methods depend mainly on the introduction of histidine mutations in specific antibody complementarity determining regions (CDRs). In the present invention, the inventors provide antibodies and other antigen-binding proteins that carry mutations outside of the complementals, thereby conferring universal pH-sensitive binding properties to the antibodies. The invention also relates to methods of isolating and generating said antigen binding proteins, compositions and medical uses thereof.
Owner:DANMARKS TEKNISKE UNIV

High-flux rapid chromatin immunoprecipitation sequencing method based on HiBiT tag and Tn5 enzyme

The invention discloses a high-flux and rapid chromatin immunoprecipitation sequencing method based on a HiBiT tag and a Tn5 enzyme, and belongs to the technical field of biology. According to the method, the high affinity characteristic of a HiBiT tag system is combined with a Tn5 enzyme in-situ library building technology, firstly, a DNA binding protein recombinant expression strain containing a HiBiT tag is constructed and subjected to induced expression, after formaldehyde crosslinking and cell lysis, an Anti-HiBiT antibody is used for rapid immunoprecipitation, and a Tn5 enzyme library is constructed; tn5 transposase is directly loaded on the magnetic beads combined with the protein and DNA fragment compound to complete fragmentation and linker connection, so that the construction of a next-generation sequencing library is quickly carried out, and the total consumed time from immunoprecipitation to the completion of library construction is less than or equal to 5 hours. Meanwhile, automatic treatment is realized through a micro experiment board (the reaction system is less than or equal to 200 microliters) and a liquid workstation, the experiment cost and the sample dosage are reduced, 48 transcription factors and 48 control samples can be synchronously treated, the efficiency is greatly improved, and an efficient tool is provided for microbial transcription regulation and control research.
Owner:TIANJIN INST OF IND BIOTECH CHINESE ACADEMY OF SCI

Synthetic non-coding RNAS

Synthetic RNA molecules comprising at least two RNA-binding protein (RBP)-binding motifs, wherein the at least two RBP-binding motifs bind the same first RBP and comprise non-identical sequences are provided. Synthetic RNA molecules comprising an RBP-binding motif that binds two orthogonal RBPs, comprising at least three RBP-binding motifs for three orthogonal RBPs or comprising a first RBP-binding motif, a second RBP-binding motif, a regulatory element and an open reading frame wherein the first and second RBP-binding motifs cooperatively enhance translation of the open reading frame are also provided. Compositions, cells and methods of use or generating the synthetic RNA molecules are also provided.
Owner:TECHNION RES & DEV FOUND LTD

DHODH polypeptide degradation agent and application thereof in preparation of medicine for preventing and / or treating DHODH-mediated diseases

The invention provides a DHODH polypeptide degradation agent and application of the DHODH polypeptide degradation agent in preparation of drugs for preventing and / or treating DHODH-mediated diseases, and belongs to the technical field of biological medicines. The invention provides a DHODH polypeptide degradation agent. The DHODH polypeptide degradation agent comprises a cell-penetrating peptide, a DHODH binding peptide, a linker and an E3 ubiquitin ligase VHL binding peptide which are sequentially connected from an N terminal to a C terminal. The DHODH polypeptide degradation agent provided by the invention can be efficiently combined with DHODH protein, and has a good anti-tumor effect on the cellular level and the animal level. The compound has a good application prospect in preparation of drugs for preventing and treating DHODH-mediated diseases, overcomes the defects that existing drugs for treating DHODH-related diseases are single in variety and insufficient in curative effect, and has important significance.
Owner:EAST CHINA UNIV OF SCI & TECH +1

Monoclonal antibody targeting RSV F protein and detection kit and application thereof

The invention relates to a monoclonal antibody targeting RSV F protein, and a related product and application thereof. The monoclonal antibody (AD5) or the antigen binding fragment of the monoclonal antibody is specifically bound with the Site III antigen epitope of the RSV F protein. The antibody AD5 disclosed by the invention has the characteristics of targeting high-conservative epitope (Site III) and having high neutralizing activity, and overcomes the main defect that the neutralizing activity is not high when the existing listed antibody targets the high-conservative epitope.
Owner:BEIJING NORMAL UNIVERSITY +1

Preparation method of lipopolysaccharide-beta-1, 3-glucan binding protein and application of lipopolysaccharide-beta-1, 3-glucan binding protein in preparation of dermatophyte broad-spectrum colloidal gold detection product

The invention belongs to the technical field of biological detection, and particularly relates to a preparation method of lipopolysaccharide-beta-1, 3-glucan binding protein and application of the lipopolysaccharide-beta-1, 3-glucan binding protein in preparation of a broad-spectrum colloidal gold detection product for dermatophytes. The prokaryotic expression system induces the procambarus clarkii-sourced lipopolysaccharide-beta-1, 3-glucan binding protein to be efficiently expressed in an inclusion body form, the optimized inclusion body purification-renaturation process is combined to realize batch preparation, and the colloidal gold chromatography technology is integrated, so that the procambarus clarkii-sourced lipopolysaccharide-beta-1, 3-glucan binding protein is obtained. The bottlenecks of the traditional detection method in sensitivity, broad spectrum and field applicability are broken through.
Owner:QINGDAO QINGMINT BIOTECHNOLOGY CO LTD

Novel reverse transcriptase and application of related fusion protein of novel reverse transcriptase in plant-guided editing

The invention discloses application of novel reverse transcriptase and related fusion protein of the novel reverse transcriptase in plant-guided editing. Candidate RT protein is obtained through systematic mining from a public database, novel reverse transcriptase cl1 with activity is screened out in combination with a fluorescence report system, and a guided editing system suitable for plants is constructed. The system tests in wheat protoplast, and verifies the editing activity of cl1 to a plurality of endogenous targets. Further combining with protein structure prediction and rational design point mutation optimization, the cl1 mutant with higher editing efficiency is obtained, and the method can be applied to accurate and effective editing of plant genomes and plant breeding and improvement.
Owner:CHINA AGRI UNIV

Mycoplasma pneumoniae p1 protein binding protein, method for producing the same, and use thereof

This application discloses a Mycoplasma pneumoniae P1 protein-binding protein, its preparation method, and its uses. The Mycoplasma pneumoniae P1 protein-binding protein includes an immunoglobulin single variable domain, wherein the immunoglobulin single variable domain comprises CDR1, CDR2, and CDR3 contained in VHH as shown in any one of SEQ ID NO: 1-8. The bivalent or multivalent nanobodies prepared using this Mycoplasma pneumoniae P1 protein-binding protein can effectively enhance their binding strength to antigens, providing a superior raw material for developing highly sensitive detection and diagnostic applications.
Owner:GUANGZHOU NAT LAB

Bicyclic urea kinase inhibitors and uses thereof

The present disclosure provides compounds of Formula (I), (II), and (III). The provided compounds are able to bind protein kinases (e.g., SIK) and may be useful in modulating (e.g., inhibiting) the activity of a protein kinase (e.g., SIK, (e.g., SIK1, SIK2, or SIK3)) in a subject or cell. The provided compounds may be useful in treating or preventing a disease (e.g., proliferative disease, musculoskeletal disease, genetic disease, hematological disease, neurological disease, painful condition, psychiatric disorder, or metabolic disorder) in a subject in need thereof. Also provided are pharmaceutical compositions, kits, methods, and uses that include or involve a compound described herein.
Owner:THE BROAD INST INC +2

Anti-CD96 antibodies and methods of use thereof

The present disclosure provides binding proteins, such as antibodies and antigen-binding fragments, which specifically bind to human CD96 receptor protein (hu-CD96) and are capable of decreasing, inhibiting, and / or fully-blocking immune regulatory effects mediated by hu-CD96. The present disclosure also provides methods of using the antibodies (and compositions thereof) to treat diseases and conditions responsive to decreasing, inhibiting and / or blocking immune regulatory function or activity mediated by CD96 binding to CD155, including effects arising from CD96 interactions with CD226 and / or TIGIT.
Owner:23ANDME GENOMICS LLC

Regulation of interactions between target molecular lipid bilayers

A combination of lipid-binding molecules and / or lipid-binding proteins with lipid components (i.e., mispids) is provided for use in modifying the interaction between target molecules and lipid membranes. This includes, for example, the use of lipid-binding molecules and / or mispids to improve the sequencing efficiency and throughput of nanopore-based sequencing systems. To sequence target molecules such as nucleic acid sequences or nucleic acid substitute polymers derived therefrom, lipid-binding molecules and / or their mispids are combined with the target molecules. The mixture is then applied to a nanopore-based sequencing chip. The target molecules are then sequenced in the presence of lipid-binding molecules and / or nanodiscs, thereby improving the capture, arrival time, and effective concentration of the target molecules across the chip membrane. Such improved efficiency is particularly beneficial, for example, when the concentration of the target molecule is low.
Owner:F HOFFMANN LA ROCHE & CO AG

Multispecific antigen binding proteins for tumor-targeting of ΓΔ1 t cells and use thereof

The present invention relates to multispecific antigen binding proteins that comprise an antigen-binding regions specific for a tumor-associated antigen (TAA), an antigen-binding region that specifically binds an epitope of a γδ T cell receptor (TCR), a γδ T cell-activating cytokine, and optionally, a γδ T cell co-stimulatory agonist. The γδ T cell-activating cytokine preferably is at least 5 one of an interleukin 21 receptor (IL21R) agonist and an interleukin 15 receptor (IL15R) agonist. The γδ T cell co-stimulatory agonist cytokine preferably is at least one of a 4-1BB agonist, a CD27 agonist and a GITR agonist. The multispecific antigen binding proteins of the invention specifically redirect and activate γδ T cell to lyse targeted tumor cells. The invention further relates to the use of such multispecific antigen binding proteins in the treatment of cancer, preferably a cancer 10 expressing the TAA.
Owner:AVIDICURE IP BV

Binding protein for human interleukin-6 receptor

PendingJP2026510418AAntibacterial agentsFungiMembrane-bound receptorsWhite blood cell
This disclosure provides an antibody (or antigen-binding protein) comprising at least one, preferably two, antigen-binding domains that bind to the human IL-6 receptor, wherein the antibody inhibits IL-6 transsignaling via the human soluble IL-6 receptor while maintaining IL-6 classical signaling via the human membrane-bound IL-6 receptor, and the antibody is capable of binding to both the human soluble IL-6 receptor and the human membrane-bound IL-6 receptor. Compositions comprising the antibody or antigen-binding protein are also provided, along with encoding nucleic acid molecules and expression vectors.
Owner:MAB DESIGN LTD

Antibody and use thereof

The present application provides an isolated antigen-binding protein, comprising: a first antigen-binding domain and a second antigen-binding domain, wherein the first antigen-binding domain specifically binds to TNF-like protein A (TL1A), and the first antigen binding domain and the second antigen binding domain are different.
Owner:EARENDIL LABS INC

Anti-cd3 antibodies and uses thereof

The present application relates to an anti-CD3 antibody and its application. The present application develops a specific antibody molecule targeting CD3 epsilon chain, which can activate T cells by combining with CD3 epsilon on T cells. A T cell binding protein containing the CD3 antibody is further designed, which can specifically target and bind to CD3 epsilon on the surface of T cells in vivo and in vitro, so as to achieve moderate activation of T cells. The CAR lentivirus containing the T cell binding protein of the present application can induce the generation of CAR-T cells in vitro and in vivo, and the CAR-T cells have good tumor cell killing efficiency.
Owner:GUANGZHOU BIO GENE TECH CO LTD

Monoclonal antibodies for detecting A35R protein and their applications

This invention relates to monoclonal antibodies for detecting A35R protein and their applications. This invention screened six antibodies, including antibody 4E7, antibody 11G12, antibody 6F10, antibody 6C11, antibody 18C3, and antibody 23A7. Specifically, this invention discloses the amino acid sequences of the heavy chain variable region and the light chain variable region of the above antibodies, as well as the amino acid sequences of their complementarity-determining regions and framework regions. Antibodies 4E7 and 11G12 can bind not only to the A35R-MPXV protein but also to its homologs A35R-CPXV, A35R-VTT8, and A35R-Variola. Antibodies 6F10, 6C11, 23A7, and 18C3 can specifically recognize the A35R-MPXV protein. The monoclonal antibodies described above all exhibit high binding capacity to the A35R protein, making them suitable for the sensitive and specific detection and prevention of monkeypox virus A35R protein. They can also be used clinically for the diagnosis and treatment of monkeypox virus infection-related diseases.
Owner:INST OF PATHOGEN BIOLOGY CHINESE ACADEMY OF MEDICAL SCI

Anti-CD25 antigen-binding proteins and uses thereof

The present application provides antigen-binding proteins (e.g., antibodies such as single-domain antibodies) that specifically bind cluster of differentiation 25 (CD25). The application also provides fusion proteins and conjugates comprising the antigen-binding proteins, polynucleotides and recombinant vectors encoding the antigen-binding proteins, as well as host cells and methods for preparing the antigen-binding proteins. The application further provides pharmaceutical compositions comprising the antigen-binding proteins.
Owner:ODYSSEY THERAPEUTICS INC

Antibody specific to Staphylococcus aureus, therapeutic method and detection method using same

We provide new monoclonal antibody inhibitors of coagulases, staphylocoagulase (“SC”) and von Willebrand factor-binding protein (“vWbp”) for treatment of S. aureus. The monoclonal antibodies are useful in targeting the SC N-terminus of SC and vWbp (respectively) and inhibiting prothrombin activation. The monoclonal antibodies are able to bind to and interfere with, modulate, and / or inhibit the binding interactions between the coagulase protein and its ligan protein prothrombin the activation of prothrombin.
Owner:CHURCH WILLIAM R

Humanized nanobody targeting BCMA and use thereof

Provided are humanized nanobody targeting BCMA and a use thereof. The nanobody is capable of binding to B-cell maturation antigen (BCMA), and the isolated antigen-binding protein comprises at least one CDR in an antibody heavy chain variable region (VH). Provided are a chimeric antigen receptor, a fusion protein, a cell and a nucleic acid molecule comprising the antigen-binding protein, and a use thereof in the treatment of tumors.
Owner:SHANGHAI ORIGINCELL MEDICAL TECHNOLOGY CO LTD

Multispecific binding proteins for cancer therapy

The present invention relates to novel multispecific binding proteins for cancer therapy, i.e. B7H6 / CD3 binding proteins. The invention further relates to nucleic acids encoding said proteins; methods for the production of said proteins; host cells expressing or capable of expressing said proteins; compositions comprising said proteins; and uses of said proteins or said compositions, in particular in the field of cancer diseases for therapeutic purposes.
Owner:BOEHRINGER INGELHEIM INT GMBH

New co-drug, co-administration and sequential administration of selective ttr ligands that eliminate mechanism-based ocular adverse reactions in the treatment of macular degeneration and ttr amyloidosis with c20-d3-retinol

PendingCN122341593ARetinoidRetinaldehyde
Based on co-drugs representing two different chemical entities and the co- and sequential administration of the two chemical entities, novel therapies for macular degeneration and TTR amyloidosis are provided. The first component (“selective TTR ligand”) is a chemical entity that binds to TTR in the RBP4 (retinol-binding protein 4)-TTR (transthyretin) complex, which participates in the delivery of retinol to the retina. This component reduces retinol transport from circulation to the retina and provides stabilization of the TTR tetramer. The second component (“C20-D3-visual chromophore-generating compound”) is a C20-D3 modified retinoid or carotenoid that, when metabolized in mammals, ultimately produces a C20-D3 visual chromophore, which is presented in the retina as C20-D3-9-cis-retinal or C20-D3-11-cis-retinal. Deuteration at C20 reduces the formation of lipofuscin biretinol, but other functions (such as providing a precursor for the synthesis of the visual chromophore 11-cis-retinaldehyde in vivo) are not reduced.
Owner:THE TRUSTEES OF COLUMBIA UNIV IN THE CITY OF NEW YORK +1

Binding protein B capable of binding with klebsiella pneumoniae and application of binding protein B

The invention relates to a binding protein B capable of binding with klebsiella pneumoniae and application of the binding protein B, and belongs to the technical field of molecular biology and protein engineering. The binding protein B provided by the invention can be specifically bound with an extramembrane part of a specific protein P24017. OMPAKLEPN of klebsiella pneumoniae, and experiments such as bimolecular fluorescence complementation and flow cytometry prove that the binding protein B has good recognition and stable binding capacity on the klebsiella pneumoniae, can be used for identifying and screening the klebsiella pneumoniae, and has good application prospects. And a key tool is provided for targeted drug development aiming at the bacterium.
Owner:QILU UNIVERSITY OF TECHNOLOGY (SHANDONG ACADEMY OF SCIENCES)

Construction of fluorescent protein-tagged tubulin and microtubule-binding protein universal bivalent vectors

ActiveCN115896146BSimplify the experimental processShorten the interactive research cycleFermentationVector-based foreign material introductionInsertion sequenceTransgene
The application provides a construction of a fluorescent protein labeled microtubulin and a microtubule binding protein universal bivalent carrier, and the process is as follows: a first stage is to construct a GFP-alpha tubulin carrier, and a second stage is to construct a GFP-alpha tubulin-mCherry universal bivalent co-expression carrier; in the second stage, 35S, mCherry and NOS sequences are inserted into a KpnI enzyme cutting site of a multiple cloning site of the GFP-alpha tubulin carrier constructed in the first stage, and a single nucleic acid enzyme cutting site is inserted into the 5' end and the 3' end of the mCherry sequence, respectively, and the single nucleic acid enzyme cutting site is XbaI, KpnI / Acc65I and AscI sequences, respectively, so as to obtain the universal bivalent carrier. The universal bivalent carrier provided by the application can express two target genes simultaneously, has the fluorescent signals of GFP and mCherry, can quickly and accurately identify a transgenic plant, is convenient for positive seedling screening, can be used for a tobacco transient expression experiment, can shorten an experimental period, and saves time and effort.
Owner:DEZHOU UNIV

A cardiovascular marker quality control and a preparation method thereof

The application belongs to the technical field of biological detection, and discloses a cardiovascular marker control article and a preparation method thereof. The cardiovascular marker control article comprises a serum matrix, antigens, a preservative and a stabilizer. The antigens include cardiac troponin I antigens, creatine kinase isoenzyme antigens, myoglobin antigens, amino-terminal brain natriuretic peptide precursor antigens, brain natriuretic peptide antigens, D-dimer antigens, heart-type fatty acid-binding protein antigens, myeloperoxidase antigens and lipoprotein phospholipase A2 antigens. The stabilizer includes at least one of D-trehalose, sucrose, glycine, inositol and polyethylene glycol. The cardiovascular marker control article can cover various cardiovascular disease markers, including heart failure, pulmonary embolism, vasculitis and atherosclerosis, myocardial injury, myocardial infarction and the like. The control article can be used as a third-party control article for indoor and inter-laboratory quality control of a cardiovascular disease screening and auxiliary diagnosis measurement system.
Owner:GUANGZHOU TEBSUN BIO TECH DEV

Anti-gprc5d antigen binding protein and use thereof

The present application relates to an isolated antigen binding protein capable of binding to a G protein-coupled receptor, class C, group 5, member D (GPRC5D) protein with an EC50 value of 1.0 µg / mL. The present application further relates to a chimeric antigen receptor comprising the antigen binding protein, and their uses in treatment of tumors.
Owner:SHANGHAI ORIGINCELL MEDICAL TECHNOLOGY CO LTD